Li-Pei J Lu, Iris C M Pelsma, Friso de Vries, Saskia P A van Hulst-Ginjaar, Wouter R van Furth, Marco J T Verstegen, Fleur L Fisher, Amir H Zamanipoor Najafadabadi, Nienke R Biermasz, Stijn W van der Meeren, Irene C Notting
{"title":"垂体腺瘤和脑膜瘤患者第三、第四和第六颅神经麻痹的恢复情况。","authors":"Li-Pei J Lu, Iris C M Pelsma, Friso de Vries, Saskia P A van Hulst-Ginjaar, Wouter R van Furth, Marco J T Verstegen, Fleur L Fisher, Amir H Zamanipoor Najafadabadi, Nienke R Biermasz, Stijn W van der Meeren, Irene C Notting","doi":"10.1097/WNO.0000000000001990","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This retrospective, observational cohort study aimed to determine recovery rate and recovery time of ocular motor nerve palsies (OMP) of third (CN III), fourth (CN IV), or sixth cranial nerves (CN VI)-and associated prognostic factors-in meningioma and pituitary adenoma (PA) patients.</p><p><strong>Methods: </strong>A total of 25 meningioma (28 eyes) and 33 PA patients (36 eyes), treated at the Leiden University Medical Center in the Netherlands from January 1, 1978 to January 31, 2021, were included. OMPs were evaluated according to a newly created recovery scale using on-clinical and orthoptic examinations, which were performed every 3-4 months until palsy recovery, or at 18 months follow-up.</p><p><strong>Results: </strong>Recovery rates of CN III (meningioma 23.5% vs PA 92.3%), CN IV (meningioma 20% vs PA 100%), and CN VI (meningioma 60% vs PA 100%) palsies were observed at 18 months follow-up, with differences between the 2 tumor types being observed in the treated patients only. Median recovery time of all OMPs combined was significantly longer in meningioma patients (37.9 ± 14.3 months vs 3.3 ± 0.1 months; P < 0.001). No significant protective or risk factors for recovery rate or time were identified.</p><p><strong>Conclusions: </strong>OMP recovery rates in treated patients were more favorable in patients with PA compared with patients with meningiomas, independent of OMP cause. With these new insights in OMP recovery, more accurate prognoses and appropriate follow-up strategies can be determined for meningioma and PA patients with OMPs.</p>","PeriodicalId":16485,"journal":{"name":"Journal of Neuro-Ophthalmology","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11319080/pdf/","citationCount":"0","resultStr":"{\"title\":\"Recovery of Third, Fourth, and Sixth Cranial Nerve Palsies in Pituitary Adenoma and Meningioma Patients.\",\"authors\":\"Li-Pei J Lu, Iris C M Pelsma, Friso de Vries, Saskia P A van Hulst-Ginjaar, Wouter R van Furth, Marco J T Verstegen, Fleur L Fisher, Amir H Zamanipoor Najafadabadi, Nienke R Biermasz, Stijn W van der Meeren, Irene C Notting\",\"doi\":\"10.1097/WNO.0000000000001990\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>This retrospective, observational cohort study aimed to determine recovery rate and recovery time of ocular motor nerve palsies (OMP) of third (CN III), fourth (CN IV), or sixth cranial nerves (CN VI)-and associated prognostic factors-in meningioma and pituitary adenoma (PA) patients.</p><p><strong>Methods: </strong>A total of 25 meningioma (28 eyes) and 33 PA patients (36 eyes), treated at the Leiden University Medical Center in the Netherlands from January 1, 1978 to January 31, 2021, were included. OMPs were evaluated according to a newly created recovery scale using on-clinical and orthoptic examinations, which were performed every 3-4 months until palsy recovery, or at 18 months follow-up.</p><p><strong>Results: </strong>Recovery rates of CN III (meningioma 23.5% vs PA 92.3%), CN IV (meningioma 20% vs PA 100%), and CN VI (meningioma 60% vs PA 100%) palsies were observed at 18 months follow-up, with differences between the 2 tumor types being observed in the treated patients only. Median recovery time of all OMPs combined was significantly longer in meningioma patients (37.9 ± 14.3 months vs 3.3 ± 0.1 months; P < 0.001). No significant protective or risk factors for recovery rate or time were identified.</p><p><strong>Conclusions: </strong>OMP recovery rates in treated patients were more favorable in patients with PA compared with patients with meningiomas, independent of OMP cause. With these new insights in OMP recovery, more accurate prognoses and appropriate follow-up strategies can be determined for meningioma and PA patients with OMPs.</p>\",\"PeriodicalId\":16485,\"journal\":{\"name\":\"Journal of Neuro-Ophthalmology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11319080/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Neuro-Ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/WNO.0000000000001990\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/9/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WNO.0000000000001990","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:这项回顾性、观察性队列研究旨在确定脑膜瘤和垂体腺瘤(PA)患者第三颅神经(CN III)、第四颅神经(CN IV)或第六颅神经(CN VI)眼运动神经麻痹(OMP)的恢复率和恢复时间,以及相关的预后因素:方法:共纳入了 25 名脑膜瘤患者(28 只眼)和 33 名垂体腺瘤患者(36 只眼),这些患者于 1978 年 1 月 1 日至 2021 年 1 月 31 日在荷兰莱顿大学医学中心接受了治疗。每3-4个月进行一次临床和正视检查,直到麻痹恢复或随访18个月,根据新创建的恢复量表对OMP进行评估:结果:在18个月的随访中观察到CN III(脑膜瘤23.5% vs PA 92.3%)、CN IV(脑膜瘤20% vs PA 100%)和CN VI(脑膜瘤60% vs PA 100%)麻痹的恢复率,仅在接受治疗的患者中观察到两种肿瘤类型之间的差异。脑膜瘤患者所有 OMPs 的中位恢复时间明显更长(37.9 ± 14.3 个月 vs 3.3 ± 0.1 个月;P < 0.001)。没有发现对恢复率或时间有明显影响的保护因素或风险因素:结论:与脑膜瘤患者相比,接受治疗的 PA 患者的 OMP 恢复率更高,这与 OMP 的病因无关。有了这些关于 OMP 恢复的新认识,就能为脑膜瘤和 PA 患者的 OMP 确定更准确的预后和更适当的随访策略。
Recovery of Third, Fourth, and Sixth Cranial Nerve Palsies in Pituitary Adenoma and Meningioma Patients.
Background: This retrospective, observational cohort study aimed to determine recovery rate and recovery time of ocular motor nerve palsies (OMP) of third (CN III), fourth (CN IV), or sixth cranial nerves (CN VI)-and associated prognostic factors-in meningioma and pituitary adenoma (PA) patients.
Methods: A total of 25 meningioma (28 eyes) and 33 PA patients (36 eyes), treated at the Leiden University Medical Center in the Netherlands from January 1, 1978 to January 31, 2021, were included. OMPs were evaluated according to a newly created recovery scale using on-clinical and orthoptic examinations, which were performed every 3-4 months until palsy recovery, or at 18 months follow-up.
Results: Recovery rates of CN III (meningioma 23.5% vs PA 92.3%), CN IV (meningioma 20% vs PA 100%), and CN VI (meningioma 60% vs PA 100%) palsies were observed at 18 months follow-up, with differences between the 2 tumor types being observed in the treated patients only. Median recovery time of all OMPs combined was significantly longer in meningioma patients (37.9 ± 14.3 months vs 3.3 ± 0.1 months; P < 0.001). No significant protective or risk factors for recovery rate or time were identified.
Conclusions: OMP recovery rates in treated patients were more favorable in patients with PA compared with patients with meningiomas, independent of OMP cause. With these new insights in OMP recovery, more accurate prognoses and appropriate follow-up strategies can be determined for meningioma and PA patients with OMPs.
期刊介绍:
The Journal of Neuro-Ophthalmology (JNO) is the official journal of the North American Neuro-Ophthalmology Society (NANOS). It is a quarterly, peer-reviewed journal that publishes original and commissioned articles related to neuro-ophthalmology.